ImmunoPrecise Antibodies Ltd.
Informe acción TSXV:IPA
Capitalización de mercado: CA$162.1m
This company listing is no longer active This company may still be operating, however this listing is no longer active. Find out why through their latest events.
See Latest Events ImmunoPrecise Antibodies Resultados de beneficios anteriores
Pasado controles de criterios 0/6 Información clave
-25.6%
Tasa de crecimiento de los beneficios
-0.6%
Tasa de crecimiento del BPA
Crecimiento de la industria Life Sciences 26.8% Tasa de crecimiento de los ingresos 28.7% Rentabilidad financiera -34.5% Margen neto -117.4% Última actualización de beneficios 31 Jul 2022
Actualizaciones de resultados anteriores recientes
First quarter 2023 earnings: EPS and revenues miss analyst expectations Sep 15
ImmunoPrecise Antibodies Ltd. to Report Q1, 2023 Results on Sep 14, 2022 Sep 10
ImmunoPrecise Antibodies Ltd. to Report Q1, 2023 Results on Sep 14, 2022 Sep 09
Full year 2022 earnings: EPS and revenues exceed analyst expectations Jul 29
ImmunoPrecise Antibodies Ltd. to Report Q4, 2022 Results on Jul 29, 2022 Jul 28
Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Dec 15
Mostrar todas las actualizaciones
ImmunoPrecise Antibodies Announces Voluntary Delisting from TSX Venture Exchange Nov 23
Price target decreased to CA$12.00 Nov 16
We Think ImmunoPrecise Antibodies (CVE:IPA) Needs To Drive Business Growth Carefully Oct 20
ImmunoPrecise Antibodies Ltd., Annual General Meeting, Dec 13, 2022 Oct 15
First quarter 2023 earnings: EPS and revenues miss analyst expectations Sep 15
ImmunoPrecise Antibodies Ltd. to Report Q1, 2023 Results on Sep 14, 2022 Sep 10
ImmunoPrecise Antibodies Ltd. to Report Q1, 2023 Results on Sep 14, 2022 Sep 09
Immunoprecise Antibodies Ltd. Announces the Continuing Success of Polytope® Tatx-03 Antibody Combination Therapy to Neutralize Variants of Concern of the Covid-19 Causative Virus Aug 30
ImmunoPrecise Antibodies Ltd. Announces Executive Changes Jul 30
Full year 2022 earnings: EPS and revenues exceed analyst expectations Jul 29
ImmunoPrecise Antibodies Ltd. to Report Q4, 2022 Results on Jul 29, 2022 Jul 28
ImmunoPrecise Antibodies Ltd. Reports the Critical Third-Party Findings of Two IND-Enabling Pre-Clinical Safety Studies Jul 13
Key Executive exercised options to buy CA$239k worth of stock. Jun 11 ImmunoPrecise Antibodies Announces Departure of Stefan Lang, Chief Business Officer May 10
Price target decreased to CA$12.00 Apr 27
Insider recently bought CA$8.6m worth of stock Apr 21
ImmunoPrecise Antibodies Ltd. Shares Outcome of Recent Laboratory Data on Their PolyTope® TATX-03 Antibody Cocktail Apr 21
Price target decreased to CA$12.00 Apr 18
ImmunoPrecise Antibodies Ltd. Releases Data Demonstrating Strong Neutralizing Potency of PolyTope® TATX-03 Antibody Cocktail Towards the SARS-CoV-2 Omicron Variant Feb 01
ImmunoPrecise Relocates European Subsidiary to LEED Certified Campus to Continue to Advance its Antibody Research Operations and Environmental Sustainability Jan 19
Consensus EPS estimates fall by 40% Dec 20
Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Dec 15
Independent Director Brian Lundstrom has left the company Dec 03
First quarter 2022 earnings released: CA$0.17 loss per share (vs CA$0.038 loss in 1Q 2021) Sep 11
Full year 2021 earnings released: CA$0.45 loss per share (vs CA$0.36 loss in FY 2020) Jul 30
ImmunoPrecise Antibodies Ltd. Announces New Results from Its Tatx-03 Polytope™ Therapy Jul 23
Chief Scientific Officer Yasmina Abdiche has left the company Jul 04
Chief Scientific Officer Yasmina Abdiche has left the company Jul 04
Chief Scientific Officer Yasmina Abdiche has left the company Jul 04
Chief Scientific Officer Yasmina Abdiche has left the company Jul 04
Chief Scientific Officer Yasmina Abdiche has left the company Jul 04
Chief Scientific Officer Yasmina Abdiche has left the company Jul 04
Chief Scientific Officer Yasmina Abdiche has left the company Jul 04
Chief Scientific Officer Yasmina Abdiche has left the company Jul 04
Chief Scientific Officer Yasmina Abdiche has left the company Jul 04
Chief Scientific Officer Yasmina Abdiche has left the company Jul 04
Chief Scientific Officer Yasmina Abdiche has left the company Jul 04
Chief Scientific Officer Yasmina Abdiche has left the company Jul 03
Chief Scientific Officer Yasmina Abdiche has left the company Jul 03
Chief Scientific Officer Yasmina Abdiche has left the company Jul 03
ImmunoPrecise Antibodies Ltd. Announces Histopathology Preclinical Data from its Polytopetm Program Confirms Lung Inflammation Reduction Jun 18
IMMUNOPRECISE to Present Preclinical Data from ImmunoPrecise's Drug Pipeline During the Bio International Partnering Event Jun 16 ImmunoPrecise Moves SARS-CoV-2 PolyTope™ Cocktail Program’s Path Toward IND Filing
CEO, President & Director recently bought CA$78k worth of stock May 14
Third quarter 2021 earnings released: CA$0.077 loss per share (vs CA$0.046 loss in 3Q 2020) Mar 20
ImmunoPrecise Antibodies Announces Results from A Comprehensive Screening of 27 Proprietary Anti-SARS-CoV-2 Therapeutic Antibodies Mar 17
ImmunoPrecise Antibodies Ltd. Announces Data from Preclinical Study of TATX-03 PolyTope Monoclonal Antibody Cocktail Candidate Against Covid-19 Feb 20
ImmunoPrecise Antibodies Ltd. has completed a Follow-on Equity Offering in the amount of $21.739141 million. Feb 09
Analysts lower EPS estimates to -CA$0.14 Dec 28
New 90-day high: CA$18.11 Dec 24
Second quarter 2021 earnings released: CA$0.03 loss per share Dec 23
Revenue and earnings beat expectations Dec 23
Earnings Update: ImmunoPrecise Antibodies Ltd. (CVE:IPA) Just Reported And Analysts Are Boosting Their Estimates Dec 23
ImmunoPrecise and LiteVax Advance SARS-CoV-2 Vaccine Candidate Dec 15
ImmunoPrecise Collaboration Enables Preclinical Manufacturing of Lead Antibodies Targeting SARS-CoV-2 Dec 13
Is ImmunoPrecise Antibodies (CVE:IPA) Using Debt In A Risky Way? Nov 25
Analysts update estimates Nov 25
Immunoprecise Antibodies Ltd. Selects More Than Ten Unique Monoclonal Antibodies for Further Preclinical Development Nov 24
ImmunoPrecise and Genmab Enter into a Technology Partnership Targeting Infectious Disease Nov 20
ImmunoPrecise Antibodies Ltd. and Mila Announce Strategic AI Partnership Nov 05
ImmunoPrecise Antibodies Ltd. Provides Update on Partnership with the University of Victoria Oct 10
First quarter earnings released Sep 30
ImmunoPrecise Antibodies Ltd. Initiates Pre-Clinical Vaccine Trials Against SARS-COV-2 Sep 26
New 90-day high: CA$2.60 Sep 26
ImmunoPrecise Antibodies Ltd. Announces New Multi-Specific SARS-CoV-2 Antibody Collaboration with Zymeworks Sep 18
New 90-day high - CA$2.05 Sep 09
Full year earnings released - CA$0.073 loss per share Aug 31
Desglose de ingresos y gastos
Cómo gana y gasta dinero ImmunoPrecise Antibodies. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos TSXV:IPA Ingresos, gastos y beneficios (CAD Millions) Fecha Ingresos Beneficios Gastos G+A Gastos de I+D 31 Jul 22 19 -23 19 11 30 Apr 22 19 -17 18 7 31 Jan 22 19 -17 16 6 31 Oct 21 19 -15 16 5 31 Jul 21 19 -10 15 3 30 Apr 21 18 -7 13 2 31 Jan 21 17 -3 12 1 31 Oct 20 17 -3 10 1 31 Jul 20 15 -3 9 1 30 Apr 20 14 -5 9 0 31 Jan 20 13 -8 9 1 31 Oct 19 11 -8 9 1 31 Jul 19 11 -9 9 1 30 Apr 19 11 -8 9 0 31 Jan 19 10 -6 9 1 31 Oct 18 9 -6 9 0 31 Jul 18 8 -5 8 0 30 Apr 18 5 -5 6 1 31 Jan 18 4 -4 5 1 31 Oct 17 3 -7 4 1 31 Jul 17 2 -6 2 1 30 Apr 17 3 -5 2 1 31 Jan 17 3 -4 1 0 31 Oct 16 3 1 1 0 31 Jul 16 2 0 1 0 30 Apr 16 2 0 1 0
Ingresos de calidad: IPA actualmente no es rentable.
Margen de beneficios creciente: IPA actualmente no es rentable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: IPA no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 25.6% al año.
Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de IPA en el último año con su promedio de 5 años, ya que actualmente no es rentable.
Beneficios vs. Industria: IPA no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Life Sciences (-4.7%).
Rentabilidad financiera
Alta ROE: IPA tiene una rentabilidad financiera negativa (-34.51%), ya que actualmente no es rentable.
Rendimiento del capital invertido
Descubre empresas con buenos resultados en el pasado Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
